% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Zhang:283140,
author = {J. Zhang and Y. Feng and G. Li and J. Zhang and X. Zhang
and Y. Zhang and Z. Qin and D. Zhuang and T. Qiu and Z. Shi
and W. Zhu and R. Zhang and Y. Wu and H. Liu$^*$ and D. Cao
and W. Hua and Y. Mao},
title = {{D}istinct aneuploid evolution of astrocytoma and
glioblastoma during recurrence.},
journal = {npj precision oncology},
volume = {7},
number = {1},
issn = {2397-768X},
address = {[London]},
publisher = {Springer Nature},
reportid = {DKFZ-2023-01927},
pages = {97},
year = {2023},
note = {DKFZ-ZMBH Alliance},
abstract = {Astrocytoma and glioblastoma (GB) are reclassified subtypes
of adult diffuse gliomas based on distinct isocitrate
dehydrogenase (IDH) mutation in the fifth edition of the WHO
Classification of Tumors of the Central Nervous System. The
recurrence of gliomas is a common and inevitable challenge,
and analyzing the distinct genomic alterations in
astrocytoma and GB could provide insights into their
progression. This study conducted a longitudinal
investigation, utilizing whole-exome sequencing, on 65
paired primary/recurrent gliomas. It examined chromosome arm
aneuploidies, copy number variations (CNVs) of
cancer-related genes and pathway enrichments during the
relapse. The veracity of these findings was verified through
the integration of our data with multiple public resources
and by corroborative immunohistochemistry (IHC). The results
revealed a greater prevalence of aneuploidy changes and
acquired CNVs in recurrent lower grade astrocytoma than in
relapsed grade 4 astrocytoma and GB. Larger aneuploidy
changes were predictive of an unfavorable prognosis in lower
grade astrocytoma (P < 0.05). Further, patients with
acquired gains of 1q, 6p or loss of 13q at recurrence had a
shorter overall survival in lower grade astrocytoma (P <
0.05); however, these prognostic effects were confined in
grade 4 astrocytoma and GB. Moreover, acquired gains of 12
genes (including VEGFA) on 6p during relapse were associated
with unfavorable prognosis for lower grade astrocytoma
patients. Notably, elevated VEGFA expression during
recurrence corresponded to poorer survival, validated
through IHC and CGGA data. To summarize, these findings
offer valuable insights into the progression of gliomas and
have implications for guiding therapeutic approaches during
recurrence.},
cin = {A240},
ddc = {610},
cid = {I:(DE-He78)A240-20160331},
pnm = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
pid = {G:(DE-HGF)POF4-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37741941},
pmc = {pmc:PMC10517995},
doi = {10.1038/s41698-023-00453-1},
url = {https://inrepo02.dkfz.de/record/283140},
}